Julian Espiritu, MD
Nephrology · South Charleston, WVNPI 1730174970
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,681 of the $214,958 with a category attached, or 72.4%. It is spread thinly across 37 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2019 at $76,061 and has fallen 59.5% since, to $30,803 in 2025. Among nephrology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,350 payments — averaging $159.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$50K
- Johnson & Johnson$46K
- Boehringer Ingelheim$31K
- Amarin Pharma, Inc.$30K
- Lilly USA, LLC$13K
- AstraZeneca$11K
- plus $34K from 31 others
What the payments were for
- Consulting fees$9,6945%
- Speaking & faculty fees$155,68172%
- Travel & lodging$19,1989%
- Food & beverage$29,91414%
- Education$4710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$214,958 in reported general payments places this provider in the 95th percentile of 55 nephrology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 502 | $643,348 |
| OzempicSemaglutide | 328 | $512,932 |
| FarxigaDapagliflozin Propanediol | 376 | $474,260 |
| KeveyisDichlorphenamide | 13 | $441,956 |
| MounjaroTirzepatide | 288 | $437,716 |
| CortrophinCorticotropin | 13 | $330,738 |
| VascepaIcosapent Ethyl | 325 | $255,806 |
| TrulicityDulaglutide | 123 | $172,987 |
| KerendiaFinerenone | 113 | $166,668 |
| InvokanaCanagliflozin | 71 | $96,982 |
| RybelsusSemaglutide | 62 | $91,773 |
| EntrestoSacubitril/Valsartan | 41 | $54,579 |
| VeltassaPatiromer Calcium Sorbitex | 21 | $38,390 |
| Icosapent Ethyl | 68 | $25,868 |
| Cinacalcet Hcl | 35 | $18,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $30,615 | $643,348502 claims |
| Lilly USA, LLCMounjaro, Trulicity | $12,997 | $610,704411 claims |
| Novo NordiskOzempic, Rybelsus | $1,808 | $604,706390 claims |
| AstraZenecaFarxiga, Lokelma | $10,975 | $483,186388 claims |
| Xeris Pharmaceuticals, Inc.Keveyis | $32 | $441,95613 claims |
| BayerKerendia | $4,265 | $166,668113 claims |
| Johnson & JohnsonInvokana | $46,316 | $96,98271 claims |
| NovartisEntresto | $437 | $54,57941 claims |
| MerckVerquvo | $438 | $10,90614 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $685 | $2,32797 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 nephrology providers in West Virginia.
Other nephrology in South Charleston
- Julie HaddySouth Charleston$3K
- Anmar AlrabadiSouth Charleston$937
- Agura AfiariSouth Charleston$177
- Abdul ZanabliS Charleston$31K
- Murad KheetanHuntington$25K
- Arijit ChakravartyMorgantown$19K
- Asif RahmanCharleston$8K
- Mirza HamiraniVienna$8K
- Michael CollinsHuntington$7K
- Khan ShabihCharleston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.